Literature DB >> 20208001

GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium.

Ruizhong Shen1, Ernesto R Drelichman, Diane Bimczok, Christina Ochsenbauer, John C Kappes, Jamie A Cannon, Daniela Tudor, Morgane Bomsel, Lesley E Smythies, Phillip D Smith.   

Abstract

Monostratified epithelial cells translocate HIV type 1 (HIV-1) from the apical to the basolateral surface via vesicular transcytosis. Because acutely transmitted HIV-1 is almost exclusively CCR5-tropic and human intestinal epithelial cells preferentially transcytose CCR5-tropic virus, we established epithelial monolayers using polarized HT-29 cells transduced to express CCR5, and an explant system using normal human rectal mucosa, to characterize biological parameters of epithelial cell transcytosis of HIV-1 and assess antiviral Ab blockade of transcytosis. The amount of cell-free HIV-1 transcytosed through the epithelial monolayer increased linearly in relation to the amount of virus applied to the apical surface, indicating transcytosis efficiency was constant (r(2) = 0.9846; p < 0.0001). The efficiency of HIV-1 transcytosis ranged between 0.05 and 1.21%, depending on the virus strain, producer cell type and gp120 V1-V3 loop signature. Inoculation of HIV-1 neutralizing Abs to the immunodominant region (7B2) or the conserved membrane proximal external region (2F5) of gp41 or to cardiolipin (IS4) onto the apical surface of epithelial monolayers prior to inoculation of virus significantly reduced HIV-1 transcytosis. 2F5 was the most potent of these IgG1 Abs. Dimeric IgA and monomeric IgA, but not polymeric IgM, 2F5 Abs also blocked HIV-1 transcytosis across the epithelium and, importantly, across explanted normal human rectal mucosa, with monomeric IgA substantially more potent than dimeric IgA in effecting transcytosis blockade. These findings underscore the potential role of transcytosis blockade in the prevention of HIV-1 transmission across columnar epithelium such as that of the rectum.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20208001      PMCID: PMC3731077          DOI: 10.4049/jimmunol.0903346

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM.

Authors:  M Bomsel; M Heyman; H Hocini; S Lagaye; L Belec; C Dupont; C Desgranges
Journal:  Immunity       Date:  1998-08       Impact factor: 31.745

2.  High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160.

Authors:  H Hocini; L Bélec; S Iscaki; B Garin; J Pillot; P Becquart; M Bomsel
Journal:  AIDS Res Hum Retroviruses       Date:  1997-09-20       Impact factor: 2.205

Review 3.  Sexual transmission of HIV.

Authors:  R A Royce; A Seña; W Cates; M S Cohen
Journal:  N Engl J Med       Date:  1997-04-10       Impact factor: 91.245

4.  Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5.

Authors:  R Kunert; F Rüker; H Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  1998-09-01       Impact factor: 2.205

5.  Cell-free human immunodeficiency virus type 1 in breast milk.

Authors:  P Lewis; R Nduati; J K Kreiss; G C John; B A Richardson; D Mbori-Ngacha; J Ndinya-Achola; J Overbaugh
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

6.  Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier.

Authors:  M Bomsel
Journal:  Nat Med       Date:  1997-01       Impact factor: 53.440

7.  An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries.

Authors:  L Persic; A Roberts; J Wilton; A Cattaneo; A Bradbury; H R Hoogenboom
Journal:  Gene       Date:  1997-03-10       Impact factor: 3.688

8.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Human immunodeficiency virus load. Quantitative assessment in semen from seropositive individuals and in spiked seminal plasma.

Authors:  S Rasheed; Z Li; D Xu
Journal:  J Reprod Med       Date:  1995-11       Impact factor: 0.142

10.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

View more
  43 in total

Review 1.  Strategies for eliciting HIV-1 inhibitory antibodies.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.

Authors:  Daniela Tudor; Huifeng Yu; Julien Maupetit; Anne-Sophie Drillet; Tahar Bouceba; Isabelle Schwartz-Cornil; Lucia Lopalco; Pierre Tuffery; Morgane Bomsel
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

Review 3.  Interactions between HIV-1 and mucosal cells in the female reproductive tract.

Authors:  Ruizhong Shen; Holly E Richter; Phillip D Smith
Journal:  Am J Reprod Immunol       Date:  2014-04-01       Impact factor: 3.886

Review 4.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 5.  Is developing an HIV-1 vaccine possible?

Authors:  Barton F Haynes; Hua-Xin Liao; Georgia D Tomaras
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

6.  Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Authors:  Jiri Mestecky; Peter F Wright; Lucia Lopalco; Herman F Staats; Pamela A Kozlowski; Zina Moldoveanu; Rashada C Alexander; Rose Kulhavy; Claudia Pastori; Leonard Maboko; Gabriele Riedner; Yuwei Zhu; Terri Wrinn; Michael Hoelscher
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-22       Impact factor: 2.205

7.  Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Authors:  Pinghuang Liu; Nicole L Yates; Xiaoying Shen; Mattia Bonsignori; M Anthony Moody; Hua-Xin Liao; Youyi Fong; S Munir Alam; R Glenn Overman; Thomas Denny; Guido Ferrari; Christina Ochsenbauer; John C Kappes; Victoria R Polonis; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; David C Montefiori; Peter Gilbert; Nelson L Michael; Jerome H Kim; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

8.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

Review 9.  The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene?

Authors:  Muki S Shey; Nigel J Garrett; Lyle R McKinnon; Jo-Ann S Passmore
Journal:  Innate Immun       Date:  2013-11-26       Impact factor: 2.680

Review 10.  Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.

Authors:  Charlene S Dezzutti; Florian Hladik
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.